

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.7	122.5	(72.6-193.7)	Male	14	10.1	138.3	(75.5-232.0)
Female	7	5.5	128.3	(51.4-264.4)	Female	13	8.6	151.6	(80.6-259.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	8.9	100.7	(45.9-191.1)
Female	63	65.3	96.5	(74.2-123.5)	Female	5	7.6	65.5	(21.1-152.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	6	7.5	80.1	(29.2-174.3)
<u>Colon / Rectum</u>					Female	3	3.2	nc	(nc-nc)
Male	21	17.0	123.7	(76.5-189.1)	<u>Ovary</u>				
Female	21	16.9	124.3	(76.9-190.0)	Female	8	5.9	135.9	(58.5-267.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.2	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	61	57.2	106.6	(81.5-136.9)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.6	nc	(nc-nc)
Male	20	8.8	228.6	(139.5-353.0)	Female	4	2.1	nc	(nc-nc)
Female	8	5.0	158.8	(68.4-312.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	0.8	767.0	(280.1-1669.4)	Male	3	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	21	13.1	160.4	(99.2-245.2)
Male	3	6.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	4.6	175.2	(75.4-345.3)	Female	18	14.8	121.3	(71.9-191.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.4	111.4	(40.7-242.5)	Male	250	208.0	120.2	(105.8-136.1)
Female	1	1.7	nc	(nc-nc)	Female	258	215.4	119.8	(105.6-135.3)
<u>Lung and Bronchus</u>									
Male	46	27.1	169.7	(124.3-226.4)					
Female	43	29.0	148.1	(107.2-199.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio (Obs / Exp) X 100;
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	20.3	103.5	(64.0-158.2)	Male	13	14.2	91.8	(48.8-157.0)
Female	7	7.0	99.6	(39.9-205.2)	Female	17	11.3	150.1	(87.4-240.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.4	183.3	(78.9-361.1)	Male	3	4.1	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	Female	5	3.1	161.3	(52.0-376.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	14	12.5	111.9	(61.1-187.8)
Female	102	90.3	112.9	(92.1-137.1)	Female	14	10.1	139.3	(76.1-233.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.3	nc	(nc-nc)	Male	10	10.8	92.9	(44.5-170.8)
<u>Colon / Rectum</u>					Female	5	4.3	115.5	(37.2-269.4)
Male	20	24.0	83.4	(50.9-128.8)	<u>Ovary</u>				
Female	22	22.1	99.4	(62.3-150.5)	Female	14	8.0	176.0	(96.1-295.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.8	85.5	(27.6-199.6)	Male	10	7.2	139.3	(66.7-256.1)
Female	3	1.4	nc	(nc-nc)	Female	4	6.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.8	nc	(nc-nc)	Male	81	79.7	101.6	(80.7-126.3)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	5.0	nc	(nc-nc)
Male	11	12.4	88.7	(44.2-158.8)	Female	4	2.7	nc	(nc-nc)
Female	5	6.8	73.9	(23.8-172.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.9	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	5	6.0	83.8	(27.0-195.6)
<u>Leukemia</u>					Female	14	17.7	78.9	(43.1-132.4)
Male	9	8.6	105.2	(48.0-199.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	6.0	183.6	(91.5-328.5)	Female	19	20.2	93.8	(56.5-146.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	7.7	nc	(nc-nc)	Male	250	290.2	86.1	(75.8-97.5)
Female	2	2.2	nc	(nc-nc)	Female	299	288.7	103.6	(92.1-116.0)
<u>Lung and Bronchus</u>									
Male	19	37.8	50.3	(30.3-78.6)					
Female	26	37.9	68.5	(44.8-100.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	12.5	160.5	(98.0-247.9)	Male	8	8.0	99.6	(42.9-196.3)
Female	5	4.4	112.7	(36.3-263.1)	Female	5	6.2	80.9	(26.1-188.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.3	310.4	(124.4-639.6)	Male	3	2.4	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.1	155.0	(77.3-277.3)
Female	44	48.0	91.6	(66.6-123.0)	Female	6	5.9	101.6	(37.1-221.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	1	5.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.5	nc	(nc-nc)
Male	15	13.7	109.5	(61.2-180.6)	<u>Ovary</u>				
Female	10	13.5	74.0	(35.4-136.1)	Female	4	4.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.4	nc	(nc-nc)	Male	8	4.2	189.2	(81.5-372.8)
Female	0	0.9	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	0.9	nc	(nc-nc)	Male	55	45.2	121.8	(91.7-158.5)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.9	nc	(nc-nc)
Male	9	6.8	133.3	(60.8-253.0)	Female	1	1.7	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	8.6	127.7	(63.7-228.6)
Male	4	4.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.5	173.1	(63.2-376.8)	Female	11	10.9	100.5	(50.1-179.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.2	nc	(nc-nc)	Male	197	166.0	118.7	(102.7-136.4)
Female	0	1.3	nc	(nc-nc)	Female	152	162.7	93.5	(79.2-109.5)
<u>Lung and Bronchus</u>									
Male	34	22.6	150.2	(104.0-209.9)					
Female	22	23.0	95.5	(59.8-144.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.6	86.1	(41.2-158.3)	Male	5	7.1	70.5	(22.7-164.4)
Female	6	4.4	137.2	(50.1-298.6)	Female	4	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	6	2.1	282.3	(103.1-614.4)
Female	2	1.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.3	111.4	(44.6-229.6)
Female	34	42.3	80.4	(55.7-112.3)	Female	9	5.6	162.0	(73.9-307.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	2.3	nc	(nc-nc)
Male	11	12.3	89.4	(44.6-159.9)	<u>Ovary</u>				
Female	12	13.2	91.1	(47.0-159.1)	Female	3	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.0	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	4.3	116.2	(37.4-271.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	45	38.5	116.8	(85.2-156.3)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.6	nc	(nc-nc)
Male	3	5.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	5	7.1	70.5	(22.7-164.6)
Male	2	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.3	nc	(nc-nc)	Female	7	9.7	72.5	(29.0-149.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.6	nc	(nc-nc)	Male	134	146.3	91.6	(76.7-108.5)
Female	0	1.3	nc	(nc-nc)	Female	144	149.2	96.5	(81.4-113.6)
<u>Lung and Bronchus</u>									
Male	18	20.6	87.6	(51.9-138.4)					
Female	36	21.9	164.6	(115.3-227.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	36.6	98.5	(68.9-136.3)	Male	20	22.7	88.0	(53.8-136.0)
Female	13	14.7	88.5	(47.1-151.3)	Female	14	18.6	75.2	(41.1-126.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.2	80.3	(25.9-187.5)	Male	5	6.7	74.3	(23.9-173.3)
Female	3	5.7	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	24	20.1	119.2	(76.4-177.4)
Female	156	142.4	109.5	(93.0-128.1)	Female	17	18.7	91.0	(53.0-145.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.6	151.6	(60.7-312.4)	Male	24	15.7	152.8	(97.9-227.4)
<u>Colon / Rectum</u>					Female	9	7.6	118.0	(53.8-224.0)
Male	42	39.6	106.1	(76.5-143.5)	<u>Ovary</u>				
Female	45	44.6	100.8	(73.5-134.9)	Female	11	13.3	83.0	(41.4-148.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	9.4	63.8	(23.3-138.9)	Male	12	12.3	97.9	(50.5-171.1)
Female	3	2.8	nc	(nc-nc)	Female	12	14.5	82.5	(42.6-144.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.5	nc	(nc-nc)	Male	110	123.5	89.1	(73.2-107.4)
Female	4	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	8.4	143.1	(73.8-249.9)
Male	22	18.5	118.9	(74.5-180.1)	Female	5	5.7	87.6	(28.2-204.4)
Female	8	11.7	68.6	(29.5-135.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.9	nc	(nc-nc)
Male	6	5.1	116.6	(42.6-253.9)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	7	8.1	86.1	(34.5-177.5)
<u>Leukemia</u>					Female	19	23.9	79.6	(47.9-124.3)
Male	9	14.0	64.4	(29.4-122.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	11.2	80.6	(36.8-153.1)	Female	25	32.4	77.2	(50.0-114.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	11.7	59.7	(23.9-123.0)	Male	461	467.6	98.6	(89.8-108.0)
Female	2	4.2	nc	(nc-nc)	Female	479	501.2	95.6	(87.2-104.5)
<u>Lung and Bronchus</u>									
Male	81	64.6	125.4	(99.6-155.9)					
Female	77	72.1	106.8	(84.2-133.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	13.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	8	10.7	74.9	(32.2-147.5)
<u>Lung and Bronchus</u>									
Male	0	1.9	nc	(nc-nc)					
Female	0	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	15.4	149.1	(94.5-223.8)	Male	14	10.6	132.1	(72.2-221.7)
Female	10	6.2	161.9	(77.5-297.8)	Female	9	9.3	96.9	(44.2-184.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	5	3.1	163.5	(52.7-381.5)
Female	6	2.8	212.6	(77.6-462.7)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	9.3	107.0	(51.2-196.8)
Female	81	71.2	113.8	(90.4-141.5)	Female	11	8.4	130.3	(64.9-233.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	14	7.8	178.8	(97.7-300.0)
<u>Colon / Rectum</u>					Female	5	3.6	140.1	(45.2-327.0)
Male	22	17.8	123.5	(77.4-187.0)	<u>Ovary</u>				
Female	29	19.3	150.2	(100.6-215.7)	Female	8	6.4	124.4	(53.6-245.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	4.3	230.9	(110.5-424.6)	Male	10	5.4	186.0	(89.1-342.1)
Female	1	1.2	nc	(nc-nc)	Female	7	6.0	116.2	(46.6-239.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	58	58.7	98.8	(75.1-127.8)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.7	nc	(nc-nc)
Male	3	9.1	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	3	5.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	13	13.8	94.1	(50.0-160.9)
Male	9	6.4	140.5	(64.1-266.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.1	98.6	(31.8-230.1)	Female	13	16.0	81.1	(43.2-138.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.7	87.9	(28.3-205.1)	Male	243	216.1	112.4	(98.7-127.5)
Female	3	1.9	nc	(nc-nc)	Female	273	236.8	115.3	(102.0-129.8)
<u>Lung and Bronchus</u>									
Male	30	28.4	105.7	(71.3-151.0)					
Female	44	31.9	137.9	(100.2-185.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	20.6	68.0	(37.1-114.1)	Male	8	13.7	58.5	(25.2-115.2)
Female	2	8.0	nc	(nc-nc)	Female	14	13.4	104.5	(57.1-175.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.8	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	0	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	12.8	62.3	(26.8-122.7)
Female	75	83.0	90.4	(71.1-113.3)	Female	14	11.2	125.5	(68.5-210.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	10	9.3	107.7	(51.5-198.0)
<u>Colon / Rectum</u>					Female	2	4.6	nc	(nc-nc)
Male	17	22.2	76.7	(44.7-122.9)	<u>Ovary</u>				
Female	19	24.5	77.4	(46.6-120.9)	Female	12	8.5	141.1	(72.8-246.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.4	nc	(nc-nc)	Male	5	6.9	72.5	(23.4-169.2)
Female	0	1.5	nc	(nc-nc)	Female	5	7.9	63.3	(20.4-147.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	3.8	nc	(nc-nc)	Male	66	71.7	92.0	(71.1-117.0)
Female	1	3.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.7	nc	(nc-nc)
Male	6	10.7	55.9	(20.4-121.7)	Female	1	3.2	nc	(nc-nc)
Female	5	6.8	73.5	(23.7-171.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	6.6	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	6.2	81.3	(26.2-189.7)
<u>Leukemia</u>					Female	5	20.6	24.2	(7.8-56.5)
Male	9	9.6	93.9	(42.8-178.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.3	68.5	(22.1-160.0)	Female	14	19.3	72.6	(39.6-121.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.9	nc	(nc-nc)	Male	199	283.0	70.3	(60.9-80.8)
Female	2	2.4	nc	(nc-nc)	Female	221	303.7	72.8	(63.5-83.0)
<u>Lung and Bronchus</u>									
Male	15	36.8	40.7	(22.8-67.2)					
Female	20	40.9	48.9	(29.9-75.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	34.1	76.1	(49.7-111.6)	Male	21	22.8	92.2	(57.1-141.0)
Female	13	12.9	100.8	(53.6-172.4)	Female	24	18.6	128.9	(82.6-191.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.7	88.9	(32.5-193.6)	Male	8	6.7	119.6	(51.5-235.7)
Female	5	5.8	86.2	(27.8-201.2)	Female	6	5.5	108.6	(39.7-236.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	25	20.1	124.4	(80.5-183.7)
Female	144	145.7	98.8	(83.4-116.4)	Female	17	17.4	97.6	(56.8-156.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.1	nc	(nc-nc)	Male	24	16.8	142.8	(91.5-212.5)
<u>Colon / Rectum</u>					Female	5	7.3	68.3	(22.0-159.4)
Male	28	38.8	72.1	(47.9-104.2)	<u>Ovary</u>				
Female	33	40.1	82.4	(56.7-115.7)	Female	17	13.2	129.2	(75.2-206.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	9.5	73.6	(29.5-151.7)	Male	12	11.9	101.2	(52.3-176.9)
Female	3	2.5	nc	(nc-nc)	Female	11	12.6	87.3	(43.5-156.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.7	nc	(nc-nc)	Male	127	128.8	98.6	(82.2-117.3)
Female	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	8.1	122.7	(58.7-225.7)
Male	12	19.5	61.5	(31.7-107.4)	Female	4	5.0	nc	(nc-nc)
Female	10	11.4	88.0	(42.1-161.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.2	141.7	(51.7-308.4)
Male	2	5.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.7	nc	(nc-nc)	Male	15	9.0	166.5	(93.1-274.7)
<u>Leukemia</u>					Female	34	26.9	126.5	(87.6-176.8)
Male	20	13.8	144.5	(88.2-223.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	10.5	124.2	(66.1-212.5)	Female	28	32.7	85.6	(56.9-123.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	12.3	81.2	(38.9-149.3)	Male	432	470.4	91.8	(83.4-100.9)
Female	2	3.9	nc	(nc-nc)	Female	451	485.9	92.8	(84.5-101.8)
<u>Lung and Bronchus</u>									
Male	37	62.9	58.8	(41.4-81.1)					
Female	41	66.6	61.6	(44.2-83.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	47.8	92.1	(66.9-123.6)	Male	32	30.7	104.3	(71.4-147.3)
Female	20	19.7	101.4	(61.9-156.7)	Female	28	27.1	103.4	(68.7-149.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.7	nc	(nc-nc)	Male	12	9.0	134.1	(69.2-234.2)
Female	8	8.3	96.9	(41.7-191.0)	Female	8	8.3	96.6	(41.6-190.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	21	27.0	77.7	(48.1-118.7)
Female	234	204.2	114.6	(100.4-130.2)	Female	29	25.8	112.3	(75.2-161.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	7.3	nc	(nc-nc)	Male	14	21.0	66.8	(36.5-112.1)
<u>Colon / Rectum</u>					Female	17	10.6	160.2	(93.3-256.5)
Male	44	52.2	84.3	(61.2-113.2)	<u>Ovary</u>				
Female	54	60.3	89.6	(67.3-116.9)	Female	20	18.7	107.0	(65.3-165.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	12.3	121.6	(68.0-200.5)	Male	12	16.0	75.0	(38.7-131.0)
Female	1	3.8	nc	(nc-nc)	Female	19	19.3	98.2	(59.1-153.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.6	nc	(nc-nc)	Male	154	160.3	96.1	(81.5-112.5)
Female	5	3.2	156.9	(50.6-366.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	11.1	90.5	(43.3-166.4)
Male	24	25.1	95.7	(61.3-142.4)	Female	5	7.6	65.7	(21.2-153.3)
Female	14	16.5	84.8	(46.3-142.3)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.2	112.5	(45.1-231.8)
Male	3	6.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	2.5	nc	(nc-nc)	Male	12	11.5	104.1	(53.7-181.8)
<u>Leukemia</u>					Female	36	37.8	95.2	(66.6-131.7)
Male	16	18.8	85.2	(48.7-138.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	15.6	83.4	(44.4-142.6)	Female	41	45.8	89.6	(64.3-121.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	15.5	115.8	(68.6-183.1)	Male	557	618.8	90.0	(82.7-97.8)
Female	3	5.8	nc	(nc-nc)	Female	695	705.5	98.5	(91.3-106.1)
<u>Lung and Bronchus</u>									
Male	71	85.0	83.5	(65.2-105.3)					
Female	77	99.6	77.3	(61.0-96.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	5.7	157.1	(71.7-298.3)	Male	2	4.1	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	20	23.0	86.8	(53.0-134.0)	Female	3	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	2	6.8	nc	(nc-nc)	<u>Ovary</u>				
Female	4	5.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	22	23.6	93.2	(58.4-141.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.8	nc	(nc-nc)
Male	5	2.4	205.4	(66.2-479.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.5	nc	(nc-nc)	Female	5	5.2	95.4	(30.7-222.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	67	83.9	79.8	(61.9-101.4)
Female	0	0.6	nc	(nc-nc)	Female	66	72.9	90.5	(70.0-115.1)
<u>Lung and Bronchus</u>									
Male	6	10.8	55.7	(20.3-121.2)					
Female	8	9.3	85.9	(37.0-169.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.0	nc	(nc-nc)	Male	5	2.2	231.8	(74.7-541.0)
Female	2	0.9	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	13	12.2	106.3	(56.5-181.7)	Female	2	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.0	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	9	12.5	71.9	(32.8-136.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.8	nc	(nc-nc)	Female	5	2.8	180.2	(58.1-420.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	40	44.5	89.9	(64.2-122.4)
Female	2	0.3	nc	(nc-nc)	Female	50	39.0	128.1	(95.1-168.9)
<u>Lung and Bronchus</u>									
Male	3	5.7	nc	(nc-nc)					
Female	5	5.1	98.4	(31.7-229.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	13	9.1	143.5	(76.4-245.5)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	9.3	75.3	(30.2-155.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	22	32.1	68.6	(43.0-103.9)
Female	0	0.2	nc	(nc-nc)	Female	26	29.6	87.7	(57.3-128.6)
<u>Lung and Bronchus</u>									
Male	2	4.3	nc	(nc-nc)					
Female	1	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	14.9	100.7	(56.3-166.1)	Male	6	10.4	57.5	(21.0-125.2)
Female	4	5.4	nc	(nc-nc)	Female	5	8.8	57.1	(18.4-133.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.2	nc	(nc-nc)	Male	6	3.0	200.5	(73.2-436.4)
Female	3	2.7	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	9.2	108.9	(52.1-200.3)
Female	66	67.6	97.7	(75.6-124.3)	Female	4	7.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	3.3	nc	(nc-nc)
Male	10	17.5	57.2	(27.4-105.3)	<u>Ovary</u>				
Female	20	16.8	119.3	(72.8-184.2)	Female	10	6.0	166.0	(79.5-305.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.2	188.5	(81.2-371.5)	Male	6	5.2	114.4	(41.8-249.1)
Female	2	1.0	nc	(nc-nc)	Female	6	5.2	116.3	(42.5-253.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	48	57.7	83.1	(61.3-110.2)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.6	nc	(nc-nc)
Male	9	9.0	99.5	(45.4-189.0)	Female	4	2.1	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.4	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	5	4.4	112.6	(36.3-262.7)
<u>Leukemia</u>					Female	23	13.8	166.7	(105.6-250.2)
Male	2	6.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	4.6	173.5	(74.7-341.9)	Female	16	15.3	104.2	(59.5-169.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.6	nc	(nc-nc)	Male	179	212.2	84.4	(72.5-97.7)
Female	4	1.7	nc	(nc-nc)	Female	237	219.1	108.1	(94.8-122.8)
<u>Lung and Bronchus</u>									
Male	27	27.5	98.1	(64.6-142.7)					
Female	39	29.0	134.6	(95.7-183.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.2	128.8	(75.0-206.3)	Male	6	8.4	71.1	(26.0-154.8)
Female	4	4.9	nc	(nc-nc)	Female	4	6.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
Female	35	50.2	69.7	(48.5-96.9)	Female	4	6.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	10	5.9	170.0	(81.4-312.7)
<u>Colon / Rectum</u>					Female	4	2.6	nc	(nc-nc)
Male	19	14.5	131.4	(79.1-205.2)	<u>Ovary</u>				
Female	12	15.1	79.5	(41.0-138.8)	Female	7	4.7	150.4	(60.3-309.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.5	173.3	(63.3-377.3)	Male	5	4.5	112.2	(36.2-261.9)
Female	0	0.9	nc	(nc-nc)	Female	5	4.8	103.3	(33.3-241.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.0	nc	(nc-nc)	Male	32	45.9	69.8	(47.7-98.5)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.1	nc	(nc-nc)
Male	9	7.0	129.4	(59.0-245.7)	Female	0	1.9	nc	(nc-nc)
Female	5	4.1	123.1	(39.7-287.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	12	9.1	131.3	(67.8-229.3)
Male	3	5.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.9	128.6	(41.4-300.1)	Female	23	11.3	203.2	(128.8-304.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.4	114.2	(36.8-266.6)	Male	178	173.0	102.9	(88.3-119.2)
Female	1	1.4	nc	(nc-nc)	Female	166	174.4	95.2	(81.3-110.8)
<u>Lung and Bronchus</u>									
Male	38	23.6	160.7	(113.7-220.6)					
Female	28	24.5	114.4	(76.0-165.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	42.5	101.2	(73.2-136.3)	Male	28	28.6	98.0	(65.1-141.7)
Female	15	16.0	93.7	(52.4-154.5)	Female	17	23.7	71.8	(41.8-114.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	8.6	128.6	(64.1-230.1)	Male	5	8.2	60.7	(19.6-141.7)
Female	7	7.3	95.6	(38.3-197.0)	Female	6	6.8	87.8	(32.1-191.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	16	25.3	63.3	(36.2-102.9)
Female	175	177.8	98.4	(84.4-114.1)	Female	19	21.7	87.6	(52.7-136.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	6.5	107.6	(43.1-221.7)	Male	24	20.4	117.9	(75.5-175.5)
<u>Colon / Rectum</u>					Female	10	9.0	110.7	(53.0-203.6)
Male	50	48.2	103.8	(77.0-136.8)	<u>Ovary</u>				
Female	40	49.6	80.7	(57.6-109.9)	Female	31	16.2	191.6	(130.1-271.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	11.5	87.0	(41.7-160.1)	Male	17	14.5	116.9	(68.1-187.2)
Female	5	3.1	163.3	(52.6-381.2)	Female	16	15.6	102.3	(58.5-166.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	3.8	236.6	(108.0-449.2)	Male	143	152.6	93.7	(79.0-110.4)
Female	1	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	10.1	69.3	(27.8-142.9)
Male	18	24.0	74.9	(44.4-118.5)	Female	7	6.2	112.4	(45.0-231.6)
Female	12	14.1	85.4	(44.1-149.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.7	89.5	(32.7-194.8)
Male	5	6.4	78.3	(25.2-182.6)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	11	11.6	94.8	(47.2-169.6)
<u>Leukemia</u>					Female	24	35.0	68.6	(44.0-102.1)
Male	8	17.5	45.8	(19.7-90.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	13.2	75.7	(36.2-139.2)	Female	43	39.8	108.2	(78.3-145.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	14.8	81.0	(41.8-141.5)	Male	563	577.7	97.5	(89.6-105.8)
Female	10	4.8	207.0	(99.1-380.8)	Female	593	602.0	98.5	(90.7-106.8)
<u>Lung and Bronchus</u>									
Male	101	76.9	131.3	(106.9-159.5)					
Female	90	82.5	109.1	(87.7-134.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	22.3	98.5	(61.7-149.1)	Male	10	13.6	73.7	(35.3-135.5)
Female	9	7.9	114.1	(52.0-216.5)	Female	6	10.3	58.4	(21.3-127.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	8	3.3	242.8	(104.5-478.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	12.0	83.1	(39.8-152.8)
Female	77	78.7	97.9	(77.2-122.3)	Female	13	10.1	128.1	(68.1-219.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	13	9.1	143.6	(76.4-245.6)
<u>Colon / Rectum</u>					Female	2	4.2	nc	(nc-nc)
Male	19	23.6	80.4	(48.4-125.5)	<u>Ovary</u>				
Female	24	23.9	100.6	(64.5-149.7)	Female	8	7.3	110.2	(47.5-217.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.6	89.7	(28.9-209.3)	Male	6	7.4	81.6	(29.8-177.6)
Female	2	1.5	nc	(nc-nc)	Female	7	7.7	90.3	(36.2-186.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	55	71.8	76.6	(57.7-99.7)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.0	nc	(nc-nc)
Male	13	10.8	119.8	(63.7-204.9)	Female	1	3.0	nc	(nc-nc)
Female	6	6.4	93.4	(34.1-203.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.2	nc	(nc-nc)
Male	6	3.0	197.4	(72.1-429.6)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<u>Leukemia</u>					Female	15	13.6	110.6	(61.9-182.4)
Male	10	8.4	119.0	(57.0-218.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.0	82.7	(26.7-193.1)	Female	18	17.8	101.0	(59.8-159.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.8	102.4	(41.0-211.0)	Male	239	277.8	86.0	(75.5-97.7)
Female	0	2.3	nc	(nc-nc)	Female	277	274.4	100.9	(89.4-113.6)
<u>Lung and Bronchus</u>									
Male	28	39.2	71.5	(47.5-103.3)					
Female	45	39.7	113.3	(82.6-151.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.4	130.0	(52.1-267.8)	Male	4	3.4	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	25	21.3	117.3	(75.9-173.2)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	4	5.9	nc	(nc-nc)	<u>Ovary</u>				
Female	3	6.2	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	8	18.4	43.4	(18.7-85.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	6	2.8	213.6	(78.0-465.0)	Female	0	0.8	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.7	136.4	(43.9-318.2)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.6	nc	(nc-nc)	Female	1	4.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	1.8	nc	(nc-nc)	Male	77	69.8	110.3	(87.0-137.8)
Female	0	0.6	nc	(nc-nc)	Female	72	73.4	98.1	(76.7-123.5)
<u>Lung and Bronchus</u>									
Male	16	9.7	165.7	(94.7-269.1)					
Female	14	10.8	129.7	(70.8-217.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.4	108.8	(43.6-224.3)	Male	3	4.5	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	4.0	nc	(nc-nc)
Female	35	28.6	122.6	(85.4-170.5)	Female	3	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.4	nc	(nc-nc)
Male	7	7.5	92.8	(37.2-191.3)	<u>Ovary</u>				
Female	6	7.7	77.4	(28.3-168.5)	Female	3	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	1.8	335.0	(122.3-729.1)	Male	3	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	21	24.0	87.5	(54.2-133.8)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.6	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.8	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	9	6.3	142.8	(65.2-271.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.4	nc	(nc-nc)	Male	83	90.7	91.5	(72.9-113.4)
Female	1	0.8	nc	(nc-nc)	Female	104	95.6	108.8	(88.9-131.9)
<u>Lung and Bronchus</u>									
Male	14	11.8	118.4	(64.7-198.7)					
Female	15	12.9	116.0	(64.9-191.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	87	70.8	122.9	(98.5-151.6)	Male	65	42.5	152.8	(117.9-194.8)
Female	26	24.3	107.0	(69.9-156.8)	Female	50	30.8	162.4	(120.5-214.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	11.1	99.3	(49.5-177.6)	Male	11	12.9	85.6	(42.7-153.1)
Female	9	9.5	95.2	(43.5-180.8)	Female	13	10.2	127.2	(67.7-217.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.1	nc	(nc-nc)	Male	39	37.4	104.2	(74.1-142.5)
Female	298	242.4	122.9	(109.4-137.7)	Female	40	31.2	128.3	(91.7-174.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	7.5	119.5	(54.5-226.9)	Male	25	28.5	87.6	(56.7-129.3)
<u>Colon / Rectum</u>					Female	14	12.8	109.2	(59.6-183.2)
Male	63	73.9	85.2	(65.5-109.0)	<u>Ovary</u>				
Female	68	71.9	94.6	(73.5-119.9)	Female	22	22.4	98.3	(61.6-148.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	19	17.9	105.9	(63.7-165.4)	Male	27	23.4	115.5	(76.1-168.0)
Female	3	4.7	nc	(nc-nc)	Female	26	23.6	110.0	(71.8-161.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.1	nc	(nc-nc)	Male	295	235.3	125.4	(111.5-140.5)
Female	2	3.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	15.9	106.9	(62.3-171.2)
Male	30	34.2	87.6	(59.1-125.1)	Female	8	9.1	88.3	(38.0-174.0)
Female	19	19.9	95.3	(57.4-148.8)	<u>Testis</u>				
<u>Larynx</u>					Male	9	5.9	151.7	(69.2-288.0)
Male	10	9.8	101.9	(48.8-187.4)	<u>Thyroid</u>				
Female	2	3.2	nc	(nc-nc)	Male	12	14.1	85.2	(44.0-148.8)
<u>Leukemia</u>					Female	25	39.1	64.0	(41.4-94.4)
Male	34	25.9	131.3	(90.9-183.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	26	18.1	143.6	(93.8-210.4)	Female	52	56.5	92.0	(68.7-120.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	22	21.9	100.6	(63.0-152.4)	Male	959	883.2	108.6	(101.8-115.7)
Female	8	7.2	111.7	(48.1-220.0)	Female	918	842.3	109.0	(102.1-116.3)
<u>Lung and Bronchus</u>									
Male	91	126.3	72.1	(58.0-88.5)					
Female	126	125.9	100.1	(83.3-119.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.6	106.7	(39.0-232.2)	Male	3	3.8	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	14	21.5	65.3	(35.6-109.5)	Female	0	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	8	6.4	124.9	(53.8-246.0)	<u>Ovary</u>				
Female	5	5.9	84.5	(27.2-197.2)	Female	1	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	24	21.6	111.3	(71.3-165.6)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	5	3.2	155.1	(50.0-361.8)	Female	2	0.7	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.2	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.6	nc	(nc-nc)	Female	7	4.8	145.1	(58.1-299.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	77	78.1	98.6	(77.8-123.2)
Female	0	0.6	nc	(nc-nc)	Female	58	71.7	80.9	(61.4-104.6)
<u>Lung and Bronchus</u>									
Male	12	10.3	116.4	(60.1-203.4)					
Female	7	9.6	73.0	(29.3-150.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	9	8.6	104.4	(47.6-198.2)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	2.2	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	10.0	59.7	(21.8-130.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	5	2.1	242.9	(78.3-566.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	25	34.5	72.4	(46.8-106.9)
Female	0	0.2	nc	(nc-nc)	Female	24	28.2	85.1	(54.5-126.7)
<u>Lung and Bronchus</u>									
Male	5	4.7	106.2	(34.2-247.9)					
Female	2	4.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	21.3	103.5	(64.8-156.7)	Male	18	12.5	143.6	(85.1-226.9)
Female	5	6.0	82.9	(26.7-193.4)	Female	3	8.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.3	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	11.2	98.6	(49.2-176.5)
Female	58	62.2	93.2	(70.8-120.5)	Female	7	7.8	89.4	(35.8-184.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.1	nc	(nc-nc)	Male	7	8.2	85.0	(34.0-175.1)
<u>Colon / Rectum</u>					Female	4	3.2	nc	(nc-nc)
Male	25	22.3	112.0	(72.5-165.4)	<u>Ovary</u>				
Female	20	18.3	109.3	(66.8-168.9)	Female	1	5.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.2	nc	(nc-nc)	Male	10	6.9	144.5	(69.2-265.7)
Female	2	1.2	nc	(nc-nc)	Female	7	5.9	118.5	(47.5-244.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	60	64.9	92.4	(70.5-118.9)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.7	nc	(nc-nc)
Male	8	9.8	81.3	(35.0-160.2)	Female	4	2.3	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	11	10.7	102.8	(51.2-183.9)
Male	7	7.9	89.0	(35.6-183.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.7	107.1	(34.5-250.0)	Female	11	14.0	78.7	(39.2-140.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.3	nc	(nc-nc)	Male	233	256.5	90.8	(79.5-103.3)
Female	0	1.8	nc	(nc-nc)	Female	187	213.7	87.5	(75.4-101.0)
<u>Lung and Bronchus</u>									
Male	24	36.7	65.4	(41.9-97.4)					
Female	30	30.8	97.5	(65.8-139.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.9	69.8	(31.9-132.5)	Male	9	9.2	98.2	(44.8-186.4)
Female	5	4.6	107.6	(34.7-251.2)	Female	6	7.7	77.8	(28.4-169.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.8	210.9	(77.0-459.1)	Male	2	2.6	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	8.1	161.0	(85.6-275.3)
Female	54	60.3	89.5	(67.2-116.8)	Female	7	6.7	104.3	(41.8-214.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	7	2.9	240.2	(96.2-494.9)
Male	14	15.4	90.9	(49.6-152.5)	<u>Ovary</u>				
Female	16	14.6	109.4	(62.5-177.7)	Female	4	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	3.8	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	51	52.6	96.9	(72.1-127.4)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.2	187.9	(68.6-409.0)
Male	5	8.1	62.0	(20.0-144.6)	Female	4	1.8	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.0	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	12.2	65.7	(28.3-129.4)
Male	6	5.5	108.9	(39.8-237.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.0	nc	(nc-nc)	Female	16	13.8	116.0	(66.2-188.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.1	nc	(nc-nc)	Male	167	188.6	88.6	(75.6-103.1)
Female	2	1.5	nc	(nc-nc)	Female	173	193.3	89.5	(76.7-103.9)
<u>Lung and Bronchus</u>									
Male	17	24.1	70.6	(41.1-113.1)					
Female	18	25.3	71.3	(42.2-112.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	15.1	72.9	(36.4-130.5)	Male	5	10.5	47.7	(15.4-111.4)
Female	7	5.5	128.0	(51.3-263.8)	Female	11	8.7	126.9	(63.3-227.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.2	187.7	(68.5-408.5)	Male	1	3.0	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	9.2	162.4	(90.8-267.8)
Female	76	66.8	113.8	(89.6-142.4)	Female	15	7.7	194.9	(109.0-321.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.5	nc	(nc-nc)	Male	7	7.7	90.6	(36.3-186.7)
<u>Colon / Rectum</u>					Female	3	3.3	nc	(nc-nc)
Male	12	17.5	68.7	(35.5-120.0)	<u>Ovary</u>				
Female	17	16.9	100.4	(58.5-160.8)	Female	2	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.3	140.6	(51.4-306.1)	Male	6	5.3	114.0	(41.6-248.1)
Female	0	1.1	nc	(nc-nc)	Female	5	5.3	94.8	(30.6-221.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	65	57.7	112.7	(87.0-143.7)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.7	136.8	(44.1-319.2)
Male	8	9.0	88.5	(38.1-174.3)	Female	2	2.1	nc	(nc-nc)
Female	5	5.1	97.2	(31.3-226.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	13	13.4	97.0	(51.6-165.8)
Male	7	6.3	110.9	(44.4-228.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.6	nc	(nc-nc)	Female	16	15.0	106.7	(61.0-173.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.6	107.4	(39.2-233.8)	Male	222	212.8	104.3	(91.0-119.0)
Female	0	1.7	nc	(nc-nc)	Female	220	218.6	100.6	(87.8-114.8)
<u>Lung and Bronchus</u>									
Male	34	27.9	121.8	(84.3-170.2)					
Female	21	29.6	71.0	(43.9-108.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	28.9	89.9	(58.7-131.8)	Male	15	18.2	82.6	(46.2-136.2)
Female	5	10.6	47.4	(15.3-110.5)	Female	9	14.8	61.0	(27.8-115.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.1	97.3	(31.4-227.1)	Male	6	5.4	112.0	(40.9-243.8)
Female	6	4.6	130.7	(47.7-284.5)	Female	5	4.5	111.6	(36.0-260.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	17	16.0	106.0	(61.7-169.7)
Female	135	113.1	119.4	(100.1-141.3)	Female	9	14.0	64.1	(29.2-121.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.0	nc	(nc-nc)	Male	4	12.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	5.8	nc	(nc-nc)
Male	22	31.3	70.3	(44.0-106.4)	<u>Ovary</u>				
Female	27	32.3	83.6	(55.1-121.6)	Female	11	10.3	106.7	(53.2-190.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.5	67.1	(21.6-156.6)	Male	9	9.7	92.9	(42.4-176.4)
Female	3	2.0	nc	(nc-nc)	Female	9	10.3	87.1	(39.8-165.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	88	97.8	90.0	(72.2-110.9)
Female	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.6	nc	(nc-nc)
Male	9	14.9	60.5	(27.6-114.8)	Female	5	4.1	123.0	(39.6-287.0)
Female	4	9.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.3	nc	(nc-nc)
Male	0	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	9	6.6	136.5	(62.3-259.1)
<u>Leukemia</u>					Female	20	20.8	96.1	(58.7-148.5)
Male	4	11.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	8.4	nc	(nc-nc)	Female	24	25.6	93.9	(60.1-139.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	9.2	nc	(nc-nc)	Male	288	371.8	77.5	(68.8-86.9)
Female	3	3.2	nc	(nc-nc)	Female	350	385.7	90.8	(81.5-100.8)
<u>Lung and Bronchus</u>									
Male	31	51.6	60.1	(40.8-85.3)					
Female	41	54.1	75.7	(54.3-102.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.1	nc	(nc-nc)	Male	5	3.8	131.5	(42.4-306.9)
Female	1	1.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	29	23.6	123.1	(82.4-176.8)	Female	4	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.1	nc	(nc-nc)
Male	6	6.3	95.7	(34.9-208.3)	<u>Ovary</u>				
Female	7	5.3	131.1	(52.5-270.1)	Female	0	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	21.5	88.5	(53.2-138.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	5	3.4	146.4	(47.2-341.7)	Female	1	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	5.1	116.9	(42.7-254.4)
Male	2	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.5	nc	(nc-nc)	Female	5	5.2	96.4	(31.1-224.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.1	nc	(nc-nc)	Male	75	77.3	97.0	(76.3-121.6)
Female	0	0.6	nc	(nc-nc)	Female	86	73.5	117.0	(93.6-144.5)
<u>Lung and Bronchus</u>									
Male	9	9.7	92.4	(42.2-175.4)					
Female	7	9.2	76.5	(30.6-157.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.9	nc	(nc-nc)	Male	5	2.5	201.8	(65.0-471.0)
Female	2	1.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	16	14.4	110.8	(63.3-180.0)	Female	2	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.1	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	12	14.3	83.9	(43.3-146.5)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.5	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	5	3.3	150.7	(48.6-351.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	59	51.7	114.1	(86.9-147.2)
Female	0	0.4	nc	(nc-nc)	Female	44	48.3	91.0	(66.1-122.2)
<u>Lung and Bronchus</u>									
Male	11	7.2	153.3	(76.4-274.3)					
Female	5	7.0	71.0	(22.9-165.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.2	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	6	1.3	447.5	(163.4-974.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	10	10.7	93.4	(44.7-171.7)	Female	3	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<u>Ovary</u>				
Female	5	3.0	169.2	(54.5-394.9)	Female	3	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	16	11.4	140.4	(80.2-228.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.8	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	42	41.9	100.4	(72.3-135.7)
Female	0	0.3	nc	(nc-nc)	Female	38	36.1	105.2	(74.4-144.4)
<u>Lung and Bronchus</u>									
Male	5	5.8	86.2	(27.8-201.2)					
Female	4	5.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	43.4	124.3	(93.4-162.2)	Male	39	27.8	140.2	(99.7-191.7)
Female	23	16.5	139.2	(88.2-208.9)	Female	34	23.1	147.0	(101.8-205.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	7.9	150.9	(77.9-263.7)	Male	9	8.2	110.3	(50.3-209.3)
Female	7	7.1	98.3	(39.4-202.6)	Female	5	7.0	71.6	(23.1-167.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.4	nc	(nc-nc)	Male	29	24.6	117.7	(78.8-169.0)
Female	177	172.9	102.3	(87.8-118.6)	Female	22	21.8	100.8	(63.1-152.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.0	nc	(nc-nc)	Male	27	19.5	138.4	(91.2-201.4)
<u>Colon / Rectum</u>					Female	13	9.0	143.8	(76.5-246.0)
Male	32	47.6	67.2	(46.0-94.9)	<u>Ovary</u>				
Female	53	50.6	104.8	(78.5-137.1)	Female	17	16.0	106.2	(61.8-170.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	11.4	104.9	(54.1-183.2)	Male	14	14.7	95.4	(52.1-160.0)
Female	3	3.1	nc	(nc-nc)	Female	13	16.2	80.3	(42.7-137.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.4	nc	(nc-nc)	Male	170	151.6	112.1	(95.9-130.3)
Female	1	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	10.1	49.6	(16.0-115.7)
Male	23	22.9	100.4	(63.6-150.7)	Female	4	6.4	nc	(nc-nc)
Female	15	13.9	107.9	(60.4-178.0)	<u>Testis</u>				
<u>Larynx</u>					Male	10	5.7	175.3	(83.9-322.5)
Male	6	6.3	95.0	(34.7-206.9)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	11	10.5	104.8	(52.3-187.6)
<u>Leukemia</u>					Female	35	32.3	108.2	(75.4-150.5)
Male	22	17.1	128.3	(80.4-194.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	13.1	98.9	(52.6-169.1)	Female	39	39.3	99.2	(70.5-135.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	14.5	89.5	(47.6-153.0)	Male	633	571.0	110.9	(102.4-119.8)
Female	13	4.9	264.9	(140.9-452.9)	Female	662	597.0	110.9	(102.6-119.7)
<u>Lung and Bronchus</u>									
Male	87	77.8	111.8	(89.6-138.0)					
Female	97	83.7	115.8	(93.9-141.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	38.2	138.9	(104.0-181.6)	Male	35	26.6	131.7	(91.7-183.1)
Female	18	13.2	136.2	(80.7-215.2)	Female	22	20.9	105.2	(65.9-159.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	8.1	86.4	(34.6-178.1)	Male	12	7.7	156.8	(80.9-273.9)
Female	6	6.4	93.1	(34.0-202.7)	Female	5	5.8	86.3	(27.8-201.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	20	23.4	85.6	(52.2-132.1)
Female	151	161.4	93.6	(79.2-109.7)	Female	20	18.7	107.2	(65.4-165.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.9	nc	(nc-nc)	Male	18	19.7	91.1	(54.0-144.1)
<u>Colon / Rectum</u>					Female	9	7.9	113.8	(51.9-216.1)
Male	28	44.3	63.3	(42.0-91.4)	<u>Ovary</u>				
Female	55	40.7	135.2	(101.8-175.9)	Female	18	14.5	124.5	(73.8-196.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	11.0	100.2	(50.0-179.4)	Male	17	13.5	126.4	(73.6-202.3)
Female	3	2.6	nc	(nc-nc)	Female	10	12.8	78.3	(37.5-144.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.6	nc	(nc-nc)	Male	140	151.3	92.5	(77.8-109.2)
Female	1	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	9.3	97.0	(44.3-184.1)
Male	27	23.1	116.7	(76.9-169.8)	Female	6	5.0	119.7	(43.7-260.5)
Female	11	12.5	88.3	(44.0-158.1)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.3	111.0	(44.5-228.6)
Male	4	6.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	2.0	nc	(nc-nc)	Male	15	11.3	132.9	(74.3-219.2)
<u>Leukemia</u>					Female	31	32.0	96.8	(65.7-137.4)
Male	23	15.9	144.6	(91.6-216.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	11.1	180.8	(110.4-279.2)	Female	29	36.8	78.9	(52.8-113.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	14.2	77.6	(38.7-138.9)	Male	573	545.8	105.0	(96.6-113.9)
Female	2	4.2	nc	(nc-nc)	Female	556	528.7	105.2	(96.6-114.3)
<u>Lung and Bronchus</u>									
Male	86	71.5	120.4	(96.3-148.6)					
Female	98	72.2	135.8	(110.2-165.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.0	99.6	(42.9-196.2)	Male	4	5.6	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	5	4.8	104.7	(33.8-244.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.0	100.5	(32.4-234.6)
Female	29	36.2	80.1	(53.7-115.1)	Female	5	4.3	117.3	(37.8-273.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.8	nc	(nc-nc)
Male	6	9.5	63.3	(23.1-137.7)	<u>Ovary</u>				
Female	6	9.6	62.3	(22.7-135.6)	Female	5	3.3	153.1	(49.3-357.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	2.3	352.2	(151.6-694.0)	Male	0	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	25	30.7	81.5	(52.7-120.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	4	4.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	5	2.8	178.5	(57.5-416.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.3	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.6	193.2	(62.3-450.8)	Female	11	8.1	136.0	(67.8-243.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.0	nc	(nc-nc)	Male	119	113.9	104.5	(86.5-125.0)
Female	0	0.9	nc	(nc-nc)	Female	123	120.0	102.5	(85.2-122.2)
<u>Lung and Bronchus</u>									
Male	25	14.7	169.7	(109.8-250.6)					
Female	16	16.1	99.6	(56.9-161.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	3	5.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	6.7	104.6	(41.9-215.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.0	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	18	23.2	77.5	(45.9-122.5)
Female	0	0.1	nc	(nc-nc)	Female	17	17.5	97.0	(56.5-155.3)
<u>Lung and Bronchus</u>									
Male	3	3.1	nc	(nc-nc)					
Female	3	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	23	19.6	117.1	(74.2-175.7)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	5	5.2	96.0	(30.9-224.0)	<u>Ovary</u>				
Female	2	4.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	24	19.0	126.5	(81.0-188.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.9	nc	(nc-nc)
Male	4	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.2	nc	(nc-nc)	Female	11	4.4	248.4	(123.8-444.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	61	65.0	93.8	(71.7-120.5)
Female	0	0.5	nc	(nc-nc)	Female	57	60.8	93.8	(71.0-121.5)
<u>Lung and Bronchus</u>									
Male	5	8.1	61.6	(19.8-143.7)					
Female	5	7.6	66.1	(21.3-154.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	350	452.6	77.3	(69.4-85.9)	Male	252	313.5	80.4	(70.8-91.0)
Female	155	178.6	86.8	(73.7-101.6)	Female	202	296.3	68.2	(59.1-78.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	76	100.7	75.5	(59.5-94.5)	Male	102	87.2	117.0	(95.4-142.0)
Female	84	90.8	92.5	(73.8-114.5)	Female	115	76.3	150.7	(124.4-180.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	10	14.3	69.8	(33.4-128.3)	Male	297	279.5	106.3	(94.5-119.1)
Female	1823	1991.0	91.6	(87.4-95.9)	Female	238	248.9	95.6	(83.8-108.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	91	80.5	113.0	(91.0-138.8)	Male	251	217.8	115.3	(101.4-130.4)
<u>Colon / Rectum</u>					Female	113	102.6	110.1	(90.8-132.4)
Male	573	511.1	112.1	(103.1-121.7)	<u>Ovary</u>				
Female	587	550.9	106.6	(98.1-115.5)	Female	185	187.4	98.7	(85.0-114.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	116	122.2	94.9	(78.4-113.8)	Male	145	155.2	93.5	(78.9-110.0)
Female	37	34.4	107.7	(75.8-148.5)	Female	185	174.2	106.2	(91.5-122.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	55	57.7	95.3	(71.8-124.0)	Male	1953	1633.1	119.6	(114.3-125.0)
Female	59	53.2	110.8	(84.4-143.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	148	107.5	137.6	(116.4-161.7)
Male	232	258.3	89.8	(78.6-102.2)	Female	104	69.5	149.7	(122.3-181.4)
Female	181	159.3	113.6	(97.7-131.5)	<u>Testis</u>				
<u>Larynx</u>					Male	93	112.7	82.5	(66.6-101.1)
Male	88	67.8	129.7	(104.0-159.8)	<u>Thyroid</u>				
Female	23	24.0	95.7	(60.7-143.6)	Male	152	138.1	110.0	(93.2-129.0)
<u>Leukemia</u>					Female	506	464.2	109.0	(99.7-118.9)
Male	146	196.8	74.2	(62.7-87.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	117	155.5	75.3	(62.2-90.2)	Female	446	448.7	99.4	(90.4-109.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	272	157.0	173.3	(153.3-195.1)	Male	6719	6287.1	106.9	(104.3-109.5)
Female	96	54.5	176.1	(142.6-215.1)	Female	6722	6913.6	97.2	(94.9-99.6)
<u>Lung and Bronchus</u>									
Male	903	818.4	110.3	(103.3-117.8)					
Female	843	928.6	90.8	(84.8-97.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	27.1	125.4	(86.8-175.3)	Male	22	16.8	131.2	(82.2-198.7)
Female	11	9.8	112.0	(55.8-200.4)	Female	16	12.4	128.8	(73.6-209.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.6	131.3	(47.9-285.7)	Male	7	5.0	139.9	(56.0-288.2)
Female	6	3.8	156.4	(57.1-340.3)	Female	3	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	15	14.7	101.7	(56.9-167.8)
Female	89	96.9	91.8	(73.7-113.0)	Female	9	12.6	71.7	(32.7-136.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	14	11.5	122.2	(66.7-205.0)
<u>Colon / Rectum</u>					Female	5	5.1	97.1	(31.3-226.6)
Male	23	28.7	80.2	(50.8-120.4)	<u>Ovary</u>				
Female	20	29.1	68.8	(42.0-106.2)	Female	14	9.0	156.0	(85.2-261.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.1	113.3	(48.8-223.3)	Male	7	9.1	77.2	(30.9-159.0)
Female	6	1.9	317.9	(116.1-691.9)	Female	11	9.6	114.6	(57.1-205.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.9	nc	(nc-nc)	Male	102	93.8	108.7	(88.6-131.9)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.2	81.2	(26.2-189.5)
Male	13	13.7	95.0	(50.6-162.5)	Female	5	3.7	136.1	(43.9-317.6)
Female	7	8.0	87.4	(35.0-180.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.9	nc	(nc-nc)
Male	7	3.9	180.6	(72.4-372.1)	<u>Thyroid</u>				
Female	4	1.3	nc	(nc-nc)	Male	1	5.9	nc	(nc-nc)
<u>Leukemia</u>					Female	17	15.7	108.1	(62.9-173.0)
Male	9	10.3	87.7	(40.0-166.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	7.4	95.2	(38.1-196.1)	Female	22	22.6	97.4	(61.0-147.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.7	57.6	(18.6-134.3)	Male	365	348.4	104.8	(94.3-116.1)
Female	1	2.9	nc	(nc-nc)	Female	341	338.6	100.7	(90.3-112.0)
<u>Lung and Bronchus</u>									
Male	56	49.1	114.1	(86.2-148.1)					
Female	63	50.5	124.9	(95.9-159.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.2	nc	(nc-nc)	Male	5	3.2	157.7	(50.8-368.0)
Female	1	1.3	nc	(nc-nc)	Female	5	2.4	204.7	(66.0-477.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	22	19.8	111.1	(69.6-168.3)	Female	4	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	<u>Ovary</u>				
Female	7	4.4	159.6	(63.9-328.9)	Female	1	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	22	18.4	119.4	(74.8-180.8)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.7	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.0	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.2	nc	(nc-nc)	Female	6	4.5	134.0	(48.9-291.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	58	65.2	88.9	(67.5-115.0)
Female	0	0.5	nc	(nc-nc)	Female	74	60.6	122.0	(95.8-153.2)
<u>Lung and Bronchus</u>									
Male	5	8.1	61.7	(19.9-144.1)					
Female	9	7.5	119.3	(54.4-226.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.2	76.3	(30.6-157.2)	Male	18	6.1	295.1	(174.8-466.5)
Female	1	2.8	nc	(nc-nc)	Female	12	4.3	276.4	(142.6-482.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	4	1.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	5.4	nc	(nc-nc)
Female	45	35.6	126.5	(92.3-169.3)	Female	2	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.7	nc	(nc-nc)
Male	5	10.5	47.7	(15.4-111.3)	<u>Ovary</u>				
Female	6	8.7	68.7	(25.1-149.5)	Female	3	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.6	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	50	36.0	138.9	(103.1-183.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.2	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.5	107.0	(42.9-220.5)
Male	7	3.6	192.6	(77.2-396.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	6	8.2	73.5	(26.8-160.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.4	nc	(nc-nc)	Male	124	127.8	97.0	(80.7-115.7)
Female	0	0.9	nc	(nc-nc)	Female	114	113.6	100.4	(82.8-120.6)
<u>Lung and Bronchus</u>									
Male	6	17.1	35.0	(12.8-76.3)					
Female	7	15.3	45.8	(18.4-94.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.8	124.6	(45.5-271.2)	Male	4	3.2	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	8	2.5	316.6	(136.3-623.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	27	20.0	135.2	(89.1-196.7)	Female	0	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	3	5.5	nc	(nc-nc)	<u>Ovary</u>				
Female	8	5.2	153.6	(66.1-302.7)	Female	4	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	18.6	69.8	(37.1-119.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	1.2	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	58	67.1	86.5	(65.6-111.8)
Female	0	0.5	nc	(nc-nc)	Female	69	65.8	104.9	(81.6-132.8)
<u>Lung and Bronchus</u>									
Male	4	8.9	nc	(nc-nc)					
Female	6	9.1	66.3	(24.2-144.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	42.6	117.4	(87.2-154.8)	Male	29	26.5	109.3	(73.2-157.0)
Female	23	16.8	136.7	(86.6-205.1)	Female	31	22.2	139.8	(95.0-198.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.4	107.5	(46.3-211.8)	Male	4	7.8	nc	(nc-nc)
Female	7	6.9	102.0	(40.9-210.1)	Female	8	7.0	114.0	(49.1-224.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	26	23.5	110.7	(72.3-162.3)
Female	187	168.2	111.2	(95.8-128.3)	Female	21	21.7	96.8	(59.9-148.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.7	140.5	(60.5-276.9)	Male	18	17.9	100.5	(59.5-158.8)
<u>Colon / Rectum</u>					Female	8	8.8	90.5	(39.0-178.3)
Male	56	45.8	122.3	(92.4-158.8)	<u>Ovary</u>				
Female	74	50.9	145.5	(114.2-182.6)	Female	13	15.5	84.1	(44.7-143.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	10.8	120.3	(64.0-205.7)	Male	13	14.1	92.0	(48.9-157.3)
Female	5	3.2	156.1	(50.3-364.3)	Female	18	16.5	109.2	(64.7-172.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.0	167.1	(53.9-390.0)	Male	132	140.1	94.2	(78.8-111.7)
Female	5	2.7	188.1	(60.6-439.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	9.7	102.9	(49.3-189.3)
Male	18	21.5	83.9	(49.7-132.5)	Female	8	6.5	124.0	(53.4-244.3)
Female	12	13.8	87.1	(45.0-152.1)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.9	nc	(nc-nc)
Male	4	5.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	2.1	287.4	(105.0-625.6)	Male	9	9.5	94.6	(43.1-179.5)
<u>Leukemia</u>					Female	35	29.8	117.4	(81.7-163.2)
Male	11	16.4	66.9	(33.4-119.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	13.1	145.1	(87.3-226.6)	Female	37	37.6	98.3	(69.2-135.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	13.4	119.3	(68.1-193.7)	Male	536	540.7	99.1	(90.9-107.9)
Female	5	4.9	102.5	(33.0-239.3)	Female	671	587.6	114.2	(105.7-123.2)
<u>Lung and Bronchus</u>									
Male	68	75.4	90.2	(70.0-114.3)					
Female	88	85.0	103.5	(83.0-127.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	19.9	85.3	(49.7-136.6)	Male	17	11.2	151.2	(88.0-242.2)
Female	8	7.2	110.4	(47.5-217.5)	Female	16	8.1	196.7	(112.4-319.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.7	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	9.9	140.7	(76.9-236.1)
Female	80	64.2	124.6	(98.8-155.1)	Female	12	8.8	135.6	(70.0-236.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	8	7.3	109.7	(47.2-216.1)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	17	20.1	84.6	(49.3-135.5)	<u>Ovary</u>				
Female	16	21.4	74.8	(42.8-121.6)	Female	4	6.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.8	nc	(nc-nc)	Male	6	6.5	92.9	(33.9-202.3)
Female	3	1.4	nc	(nc-nc)	Female	4	7.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	75	62.4	120.1	(94.5-150.6)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.4	nc	(nc-nc)
Male	7	8.8	79.8	(32.0-164.4)	Female	0	2.7	nc	(nc-nc)
Female	5	5.5	91.6	(29.5-213.7)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	8	8.9	89.9	(38.7-177.2)
Male	6	7.0	86.1	(31.5-187.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.2	nc	(nc-nc)	Female	15	15.2	98.9	(55.3-163.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.7	nc	(nc-nc)	Male	237	236.3	100.3	(87.9-113.9)
Female	0	2.0	nc	(nc-nc)	Female	216	232.1	93.1	(81.1-106.3)
<u>Lung and Bronchus</u>									
Male	29	34.6	83.7	(56.1-120.3)					
Female	17	35.5	47.8	(27.8-76.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	23.2	116.2	(76.6-169.1)	Male	19	16.5	115.0	(69.2-179.5)
Female	12	7.5	160.4	(82.8-280.3)	Female	17	12.0	141.7	(82.5-226.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	117.2	(42.8-255.2)	Male	2	4.7	nc	(nc-nc)
Female	7	3.8	185.0	(74.1-381.2)	Female	3	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	10	14.6	68.4	(32.7-125.7)
Female	88	89.5	98.4	(78.9-121.2)	Female	8	10.6	75.8	(32.7-149.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.3	nc	(nc-nc)	Male	7	12.4	56.5	(22.6-116.4)
<u>Colon / Rectum</u>					Female	6	4.5	134.5	(49.1-292.8)
Male	24	27.4	87.5	(56.1-130.2)	<u>Ovary</u>				
Female	25	23.3	107.5	(69.5-158.6)	Female	10	8.2	122.6	(58.7-225.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.7	119.7	(51.6-235.9)	Male	8	8.3	96.9	(41.7-191.0)
Female	1	1.4	nc	(nc-nc)	Female	12	7.2	166.0	(85.7-289.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.5	nc	(nc-nc)	Male	88	91.6	96.1	(77.1-118.4)
Female	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.7	nc	(nc-nc)
Male	11	14.3	76.9	(38.3-137.5)	Female	5	2.9	172.3	(55.5-402.0)
Female	4	6.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.5	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	13	7.3	178.1	(94.7-304.6)
<u>Leukemia</u>					Female	27	18.6	145.2	(95.6-211.2)
Male	5	10.0	50.2	(16.2-117.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.4	nc	(nc-nc)	Female	15	20.2	74.4	(41.6-122.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	8.8	159.5	(87.1-267.6)	Male	332	336.0	98.8	(88.5-110.0)
Female	3	2.3	nc	(nc-nc)	Female	299	297.3	100.6	(89.5-112.6)
<u>Lung and Bronchus</u>									
Male	55	43.1	127.6	(96.1-166.1)					
Female	31	39.9	77.6	(52.7-110.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.1	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.4	205.6	(66.3-479.9)
Female	16	16.6	96.6	(55.2-156.9)	Female	4	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.8	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	4.2	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	11	16.4	67.1	(33.4-120.0)
Female	2	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.1	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.1	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	49	57.9	84.6	(62.6-111.9)
Female	0	0.4	nc	(nc-nc)	Female	51	54.1	94.3	(70.2-124.0)
<u>Lung and Bronchus</u>									
Male	6	7.7	78.0	(28.5-169.7)					
Female	11	7.4	148.5	(74.0-265.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	77	82.9	92.9	(73.3-116.1)	Male	32	55.7	57.5	(39.3-81.2)
Female	28	31.8	88.0	(58.5-127.3)	Female	28	48.5	57.7	(38.3-83.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	17.3	69.3	(35.8-121.1)	Male	14	16.0	87.4	(47.7-146.6)
Female	15	15.3	98.0	(54.8-161.6)	Female	14	13.6	102.6	(56.0-172.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.7	nc	(nc-nc)	Male	43	49.4	87.1	(63.0-117.3)
Female	327	359.3	91.0	(81.4-101.4)	Female	43	43.7	98.4	(71.2-132.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	25	13.4	187.2	(121.1-276.4)	Male	39	39.7	98.1	(69.8-134.2)
<u>Colon / Rectum</u>					Female	17	18.2	93.3	(54.3-149.4)
Male	114	93.5	121.9	(100.5-146.4)	<u>Ovary</u>				
Female	109	97.7	111.5	(91.6-134.5)	Female	40	32.9	121.6	(86.9-165.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	22	22.6	97.5	(61.1-147.6)	Male	32	28.5	112.1	(76.7-158.3)
Female	8	6.1	130.8	(56.3-257.7)	Female	37	31.0	119.5	(84.1-164.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	7.8	nc	(nc-nc)	Male	320	303.4	105.5	(94.2-117.7)
Female	8	6.8	117.1	(50.4-230.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	24	19.7	122.0	(78.2-181.6)
Male	57	47.0	121.4	(91.9-157.3)	Female	15	12.3	122.4	(68.4-201.9)
Female	26	28.5	91.3	(59.7-133.9)	<u>Testis</u>				
<u>Larynx</u>					Male	12	13.6	88.1	(45.5-153.8)
Male	17	12.5	135.7	(79.0-217.2)	<u>Thyroid</u>				
Female	6	4.4	137.5	(50.2-299.3)	Male	31	22.7	136.8	(92.9-194.2)
<u>Leukemia</u>					Female	101	72.7	138.8	(113.1-168.7)
Male	26	34.9	74.6	(48.7-109.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	22	26.9	81.8	(51.2-123.8)	Female	78	81.4	95.9	(75.8-119.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	36	29.0	124.0	(86.9-171.7)	Male	1187	1136.5	104.4	(98.6-110.6)
Female	16	9.8	164.0	(93.7-266.4)	Female	1271	1216.1	104.5	(98.9-110.4)
<u>Lung and Bronchus</u>									
Male	184	150.9	122.0	(105.0-140.9)					
Female	202	166.3	121.4	(105.3-139.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.0	150.4	(54.9-327.4)	Male	4	2.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	16	15.7	101.6	(58.1-165.1)	Female	3	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	0.8	nc	(nc-nc)
Male	3	4.5	nc	(nc-nc)	<u>Ovary</u>				
Female	7	4.2	166.1	(66.5-342.2)	Female	1	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	15.8	88.7	(48.5-148.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.8	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	5	3.7	136.9	(44.1-319.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	46	55.5	82.8	(60.6-110.5)
Female	3	0.4	nc	(nc-nc)	Female	57	52.8	107.9	(81.7-139.8)
<u>Lung and Bronchus</u>									
Male	10	7.5	133.7	(64.0-245.8)					
Female	8	7.7	104.5	(45.0-205.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	55.2	97.9	(73.5-127.7)	Male	42	35.5	118.4	(85.3-160.0)
Female	14	20.9	66.9	(36.5-112.2)	Female	43	32.6	131.9	(95.4-177.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	10.5	133.9	(73.1-224.7)	Male	10	10.2	97.8	(46.8-179.8)
Female	10	9.9	100.6	(48.2-185.1)	Female	8	8.9	89.8	(38.7-176.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	40	31.4	127.4	(91.0-173.4)
Female	253	223.9	113.0	(99.5-127.8)	Female	35	28.5	122.9	(85.6-170.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	8.7	nc	(nc-nc)	Male	21	24.0	87.6	(54.2-133.9)
<u>Colon / Rectum</u>					Female	8	11.7	68.2	(29.4-134.4)
Male	38	59.4	63.9	(45.2-87.8)	<u>Ovary</u>				
Female	44	63.9	68.8	(50.0-92.4)	Female	32	21.1	151.3	(103.5-213.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	14.3	41.9	(15.3-91.2)	Male	22	18.5	118.7	(74.4-179.8)
Female	2	4.0	nc	(nc-nc)	Female	26	20.6	126.3	(82.5-185.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	5.0	nc	(nc-nc)	Male	192	189.4	101.4	(87.5-116.8)
Female	6	5.2	114.4	(41.8-249.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	12.7	78.8	(37.7-144.9)
Male	33	28.8	114.7	(79.0-161.2)	Female	9	8.1	111.2	(50.7-211.1)
Female	18	18.1	99.5	(58.9-157.2)	<u>Testis</u>				
<u>Larynx</u>					Male	13	9.4	138.6	(73.7-236.9)
Male	1	7.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	2.7	nc	(nc-nc)	Male	17	13.8	123.5	(71.9-197.7)
<u>Leukemia</u>					Female	53	48.7	108.8	(81.5-142.3)
Male	33	22.1	149.1	(102.6-209.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	26	17.5	148.6	(97.0-217.7)	Female	47	51.7	90.9	(66.8-120.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	17.7	39.5	(15.8-81.3)	Male	674	722.3	93.3	(86.4-100.6)
Female	6	6.3	94.9	(34.7-206.6)	Female	779	782.9	99.5	(92.6-106.7)
<u>Lung and Bronchus</u>									
Male	66	98.2	67.2	(52.0-85.5)					
Female	79	106.8	74.0	(58.5-92.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	12	9.7	123.7	(63.9-216.1)	Female	0	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.3	107.2	(51.3-197.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	26	33.0	78.8	(51.4-115.4)
Female	0	0.3	nc	(nc-nc)	Female	38	32.6	116.5	(82.5-159.9)
<u>Lung and Bronchus</u>									
Male	1	4.5	nc	(nc-nc)					
Female	5	4.7	106.3	(34.3-248.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	30.0	100.1	(67.6-143.0)	Male	15	19.0	79.1	(44.2-130.5)
Female	7	10.8	64.9	(26.0-133.8)	Female	16	14.7	108.9	(62.2-176.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.3	169.4	(77.3-321.7)	Male	6	5.6	107.3	(39.2-233.5)
Female	2	4.5	nc	(nc-nc)	Female	5	4.6	109.8	(35.4-256.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	26	16.6	156.4	(102.2-229.2)
Female	123	112.5	109.3	(90.9-130.5)	Female	15	14.2	105.9	(59.2-174.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.8	nc	(nc-nc)	Male	9	12.8	70.0	(32.0-133.0)
<u>Colon / Rectum</u>					Female	4	5.8	nc	(nc-nc)
Male	32	32.1	99.7	(68.2-140.8)	<u>Ovary</u>				
Female	30	32.1	93.6	(63.1-133.6)	Female	7	10.3	68.2	(27.3-140.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.8	nc	(nc-nc)	Male	11	10.0	109.8	(54.8-196.5)
Female	1	2.1	nc	(nc-nc)	Female	13	10.4	124.6	(66.3-213.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	99	102.1	97.0	(78.8-118.1)
Female	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.9	72.9	(23.5-170.0)
Male	18	15.5	116.0	(68.7-183.3)	Female	5	4.0	124.4	(40.1-290.3)
Female	8	9.2	87.1	(37.5-171.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.5	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	11	6.9	159.4	(79.5-285.2)
<u>Leukemia</u>					Female	28	20.2	138.5	(92.0-200.2)
Male	18	11.5	156.1	(92.4-246.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	8.4	83.2	(33.3-171.5)	Female	31	25.7	120.7	(82.0-171.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	9.6	83.1	(35.8-163.7)	Male	398	386.9	102.9	(93.0-113.5)
Female	3	3.2	nc	(nc-nc)	Female	399	387.5	103.0	(93.1-113.6)
<u>Lung and Bronchus</u>									
Male	47	54.4	86.5	(63.5-115.0)					
Female	55	56.8	96.8	(72.9-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	73.3	58.7	(42.4-79.0)	Male	56	51.3	109.2	(82.5-141.8)
Female	20	27.9	71.8	(43.8-110.9)	Female	41	49.6	82.7	(59.4-112.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	16.6	102.6	(59.7-164.3)	Male	16	13.9	115.1	(65.8-187.0)
Female	14	14.8	94.8	(51.8-159.1)	Female	11	12.0	91.6	(45.7-163.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.3	nc	(nc-nc)	Male	37	45.6	81.2	(57.1-111.9)
Female	300	313.8	95.6	(85.1-107.0)	Female	32	39.7	80.6	(55.1-113.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	13.6	66.1	(30.2-125.5)	Male	33	34.4	96.0	(66.0-134.8)
<u>Colon / Rectum</u>					Female	13	16.3	79.7	(42.4-136.3)
Male	77	81.5	94.5	(74.6-118.2)	<u>Ovary</u>				
Female	76	85.4	89.0	(70.1-111.4)	Female	18	30.1	59.9	(35.5-94.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	19.5	46.1	(21.1-87.6)	Male	29	25.0	116.0	(77.7-166.6)
Female	6	5.4	111.4	(40.7-242.4)	Female	25	27.2	92.0	(59.6-135.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	10.7	65.4	(26.2-134.8)	Male	243	260.8	93.2	(81.8-105.6)
Female	6	9.5	62.9	(23.0-136.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	17.3	69.4	(35.8-121.2)
Male	26	41.2	63.1	(41.2-92.5)	Female	9	10.8	83.6	(38.1-158.6)
Female	11	25.2	43.7	(21.8-78.1)	<u>Testis</u>				
<u>Larynx</u>					Male	24	22.4	107.1	(68.6-159.4)
Male	8	10.8	74.1	(31.9-146.0)	<u>Thyroid</u>				
Female	2	3.8	nc	(nc-nc)	Male	29	23.3	124.4	(83.3-178.6)
<u>Leukemia</u>					Female	79	79.8	99.0	(78.4-123.4)
Male	20	32.0	62.4	(38.1-96.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	24.6	81.3	(49.6-125.6)	Female	70	72.3	96.9	(75.5-122.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	24.7	80.9	(49.4-124.9)	Male	876	1017.3	86.1	(80.5-92.0)
Female	11	8.6	127.5	(63.5-228.1)	Female	952	1101.8	86.4	(81.0-92.1)
<u>Lung and Bronchus</u>									
Male	109	131.7	82.8	(68.0-99.8)					
Female	107	146.2	73.2	(60.0-88.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	26.5	79.1	(49.0-120.9)	Male	18	16.4	109.8	(65.0-173.5)
Female	9	10.1	88.7	(40.5-168.4)	Female	14	13.4	104.8	(57.2-175.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.6	nc	(nc-nc)	Male	6	4.9	123.1	(45.0-268.0)
Female	5	4.1	120.9	(39.0-282.2)	Female	8	4.2	189.2	(81.5-372.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	12	14.6	82.3	(42.5-143.8)
Female	95	101.6	93.5	(75.7-114.4)	Female	16	13.1	122.4	(69.9-198.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	10	11.2	89.3	(42.7-164.2)
<u>Colon / Rectum</u>					Female	10	5.4	186.9	(89.5-343.7)
Male	31	28.5	108.6	(73.8-154.2)	<u>Ovary</u>				
Female	29	31.1	93.3	(62.5-134.0)	Female	7	9.4	74.8	(29.9-154.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.8	88.7	(32.4-193.1)	Male	10	8.8	113.2	(54.2-208.2)
Female	1	1.9	nc	(nc-nc)	Female	9	10.0	89.8	(41.0-170.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	81	88.0	92.1	(73.1-114.4)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	6.1	nc	(nc-nc)
Male	11	13.3	82.7	(41.2-148.0)	Female	2	4.0	nc	(nc-nc)
Female	4	8.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.8	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	10	5.8	171.6	(82.2-315.7)
<u>Leukemia</u>					Female	28	17.9	156.0	(103.7-225.5)
Male	15	10.2	146.8	(82.1-242.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.9	75.7	(27.6-164.7)	Female	26	22.7	114.4	(74.7-167.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	8.4	nc	(nc-nc)	Male	322	336.7	95.6	(85.5-106.7)
Female	0	2.9	nc	(nc-nc)	Female	368	354.0	104.0	(93.6-115.1)
<u>Lung and Bronchus</u>									
Male	40	46.7	85.6	(61.1-116.6)					
Female	61	50.1	121.9	(93.2-156.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;